tetano
Editor, Senior Moderator
PLoS One
. 2025 Jan 24;20(1):e0317965.
doi: 10.1371/journal.pone.0317965. eCollection 2025. Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function
Annette Audigé[SUP] 1 [/SUP], Alain Amstutz[SUP] 2 3 4 [/SUP], Macé M Schuurmans[SUP] 5 [/SUP], Patrizia Amico[SUP] 6 [/SUP], Dominique L Braun[SUP] 1 7 [/SUP], Marcel P Stoeckle[SUP] 8 [/SUP], Barbara Hasse[SUP] 7 [/SUP], René Hage[SUP] 5 [/SUP], Dominik Damm[SUP] 5 [/SUP], Michael Tamm[SUP] 9 [/SUP], Nicolas J Mueller[SUP] 7 [/SUP], Huldrych F Günthard[SUP] 1 7 [/SUP], Michael T Koller[SUP] 6 10 [/SUP], Christof M Schönenberger[SUP] 2 [/SUP], Alexandra Griessbach[SUP] 2 [/SUP], Niklaus D Labhardt[SUP] 2 [/SUP], Roger D Kouyos[SUP] 1 7 [/SUP], Alexandra Trkola[SUP] 1 [/SUP], Michael Huber[SUP] 1 [/SUP], Katharina Kusejko[SUP] 1 7 [/SUP], Heiner C Bucher[SUP] 2 [/SUP], Irene A Abela[SUP] 1 7 [/SUP], Matthias Briel[SUP] 2 11 [/SUP], Frédérique Chammartin[SUP] 2 [/SUP], Benjamin Speich[SUP] 2 [/SUP]; Swiss HIV Cohort Study, and the Swiss Transplant Cohort Study
Affiliations
T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially available T-cell tests. We assessed 173 blood samples from 81 participants (62 samples from 35 PWH; 111 samples from 46 SOT recipients [lung and kidney]) with two commercial SARS-CoV-2 Interferon-γ (IFN-γ) release assays (IGRA; SARS-CoV-2 IGRA by Euroimmun, and IGRA SARS-CoV-2 by Roche). The reliability between the tests was judged as low (Cohen's kappa [κ] = 0.20; overall percent agreement [OPA] = 66%). A high proportion of tests were invalid (22% Euroimmun; 8% Roche). When excluding these invalid tests, the agreement was higher (κ = 0.43; OPA = 90%). The low reliability between the two T-cell tests indicates that results should be interpreted with caution in SOT recipients and PWH and that SARS-CoV-2 T-cell tests need to be optimized and further validated for use in vulnerable patient populations.
. 2025 Jan 24;20(1):e0317965.
doi: 10.1371/journal.pone.0317965. eCollection 2025. Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function
Annette Audigé[SUP] 1 [/SUP], Alain Amstutz[SUP] 2 3 4 [/SUP], Macé M Schuurmans[SUP] 5 [/SUP], Patrizia Amico[SUP] 6 [/SUP], Dominique L Braun[SUP] 1 7 [/SUP], Marcel P Stoeckle[SUP] 8 [/SUP], Barbara Hasse[SUP] 7 [/SUP], René Hage[SUP] 5 [/SUP], Dominik Damm[SUP] 5 [/SUP], Michael Tamm[SUP] 9 [/SUP], Nicolas J Mueller[SUP] 7 [/SUP], Huldrych F Günthard[SUP] 1 7 [/SUP], Michael T Koller[SUP] 6 10 [/SUP], Christof M Schönenberger[SUP] 2 [/SUP], Alexandra Griessbach[SUP] 2 [/SUP], Niklaus D Labhardt[SUP] 2 [/SUP], Roger D Kouyos[SUP] 1 7 [/SUP], Alexandra Trkola[SUP] 1 [/SUP], Michael Huber[SUP] 1 [/SUP], Katharina Kusejko[SUP] 1 7 [/SUP], Heiner C Bucher[SUP] 2 [/SUP], Irene A Abela[SUP] 1 7 [/SUP], Matthias Briel[SUP] 2 11 [/SUP], Frédérique Chammartin[SUP] 2 [/SUP], Benjamin Speich[SUP] 2 [/SUP]; Swiss HIV Cohort Study, and the Swiss Transplant Cohort Study
Affiliations
- PMID: 39854310
- PMCID: PMC11761106
- DOI: 10.1371/journal.pone.0317965
T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially available T-cell tests. We assessed 173 blood samples from 81 participants (62 samples from 35 PWH; 111 samples from 46 SOT recipients [lung and kidney]) with two commercial SARS-CoV-2 Interferon-γ (IFN-γ) release assays (IGRA; SARS-CoV-2 IGRA by Euroimmun, and IGRA SARS-CoV-2 by Roche). The reliability between the tests was judged as low (Cohen's kappa [κ] = 0.20; overall percent agreement [OPA] = 66%). A high proportion of tests were invalid (22% Euroimmun; 8% Roche). When excluding these invalid tests, the agreement was higher (κ = 0.43; OPA = 90%). The low reliability between the two T-cell tests indicates that results should be interpreted with caution in SOT recipients and PWH and that SARS-CoV-2 T-cell tests need to be optimized and further validated for use in vulnerable patient populations.